Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.97

-2.0%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BMcV who wrote (14966)	12/27/2004 5:06:12 PM
From: software salesperson	Read Replies (1) of 52153

here's an idea about aleve: i don't believe the results. consider that the implicated aleve dose is 220 mg. twice/daily. before aleve was sold otc, naprosyn was sold at doses of 250/375/500 twice/daily, with 375 mg. being, i believe, the standard dose. naprosyn was sold from at least 1976 to 1999, when the cox-2 inhibitors came on the market. during that time, many billions of naprosyn were sold.there had to be a lot of people who were taking naprosyn alone. if there truly were a cardio issue with naprosyn, it would likely have shown up a long time ago. so, extremely unlikely that the lower dose product, i.e. aleve, has an issue. sales

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next